title: [Severe interstitial lung disease due to treatment with infliximab and azathioprine].
abstract: A 41-year-old man developed severe interstitial lung disease (ILD) after treatment with infliximab (IFX) and azathioprine (AZA). A relapse of ulcerative colitis was treated with corticosteroids (CS) and IFX as rescue therapy. Following remission AZA was given as prophylaxis. AZA was initiated the same day as the third infusion of IFX (week 6). Within a few days he developed signs of lung involvement progressing into severe ILD. A high resolution computed tomography showed subacute hypersensitive pneumonitis. He was treated with oxygen and high dose CS. After three months his state of health had returned to normal.
authors.affiliation: Institut for Molekylær Medicin, Kardiovaskulær og Renal Forskning, Syddansk Universitet, Odense. larskochhansen@dadlnet.dk.
authors.forename: Lars Koch
authors.initials: LK
authors.lastname: Hansen
authors.forename: Stefano
authors.initials: S
authors.lastname: Cecere
authors.forename: Thøger
authors.initials: T
authors.lastname: Thøgersen
mesh_terms: D000328:Adult; D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab / Q000009:adverse effects*; D008297:Male; D014057:Tomography, X-Ray Computed
chemical_list: D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab; D001379:Azathioprine